|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn7 |
calpain 7 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr16:6,545,630...6,581,908
Ensembl chr16:6,545,731...6,581,905
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein] [Swainsonine co-treated with aloxistatin] results in increased cleavage of CASP3 protein |
CTD |
PMID:26853465 PMID:33186601 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of CASP9 protein] |
CTD |
PMID:34523043 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 PMID:32186374 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein |
CTD |
PMID:32186374 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein] |
CTD |
PMID:30821613 |
|
NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein] |
CTD |
PMID:30821613 |
|
NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein] |
CTD |
PMID:30821613 |
|
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of GAPDH protein] |
CTD |
PMID:34523043 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein |
CTD |
PMID:32186374 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
ISO |
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; aloxistatin promotes the reaction [indatraline results in increased lipidation of MAP1LC3B protein] aloxistatin results in increased lipidation of MAP1LC3B protein [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein |
CTD |
PMID:26483381 PMID:27635674 PMID:32397857 PMID:33124469 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; aloxistatin promotes the reaction [indatraline results in increased expression of SQSTM1 protein]; aloxistatin promotes the reaction [Sertraline results in increased expression of SQSTM1 protein] aloxistatin results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein |
CTD |
PMID:26483381 PMID:32186374 PMID:32773031 PMID:33124469 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
lipstatin analog results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:20577697 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases phosphorylation |
ISO |
lipstatin analog results in increased phosphorylation of EIF2A protein |
CTD |
PMID:20577697 |
|
NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
|
|
G |
Fasn |
fatty acid synthase |
affects binding |
ISO |
lipstatin analog binds to FASN protein |
CTD |
PMID:20577697 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
leucine methyl ester inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:21748807 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
decreases activity |
ISO |
orlistat results in decreased activity of ABHD12 protein |
CTD |
PMID:18657971 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd16a |
abhydrolase domain containing 16A, phospholipase |
decreases activity |
ISO |
orlistat results in decreased activity of ABHD16A protein |
CTD |
PMID:18657971 |
|
NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions decreases expression |
ISO |
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] Orlistat results in decreased expression of ACACA mRNA |
CTD |
PMID:32347045 PMID:33476690 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Orlistat results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
decreases expression |
ISO |
Orlistat results in decreased expression of ACOT8 protein |
CTD |
PMID:30667213 |
|
NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP ISO |
orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein] |
CTD |
PMID:25087745 PMID:33476690 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
orlistat results in increased expression of ATF4 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of BAX mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of BCL2 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage multiple interactions |
ISO EXP |
orlistat results in increased activity of CASP3 protein orlistat results in increased cleavage of CASP3 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA] |
CTD |
PMID:17283163 PMID:20805790 PMID:21723078 PMID:32450208 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO EXP |
orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA] |
CTD |
PMID:18796435 PMID:20577697 PMID:32450208 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
orlistat results in increased activity of CASP9 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP9 mRNA] |
CTD |
PMID:20805790 PMID:32450208 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
EXP ISO |
Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein] Orlistat results in decreased expression of CAT protein |
CTD |
PMID:25087745 PMID:30667213 PMID:32450208 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cck |
cholecystokinin |
multiple interactions decreases secretion |
ISO |
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein] orlistat results in decreased secretion of CCK protein |
CTD |
PMID:11408251 PMID:18303078 PMID:18647814 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CCNA2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO |
Orlistat results in increased expression of CCND1 protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein] |
CTD |
PMID:30667213 PMID:32045588 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
Orlistat results in increased expression of CCNE1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd34 |
CD34 molecule |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein] |
CTD |
PMID:32045588 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK1 protein |
CTD |
PMID:30667213 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK4 protein |
CTD |
PMID:30667213 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Orlistat results in increased expression of CDKN1A protein |
CTD |
PMID:30667213 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
orlistat results in increased expression of CDKN1B protein |
CTD |
PMID:15138278 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cel |
carboxyl ester lipase |
decreases activity |
ISO |
orlistat results in decreased activity of CEL protein |
CTD |
PMID:11592731 PMID:12381337 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Clps |
colipase |
multiple interactions |
ISO |
orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] |
CTD |
PMID:15158758 |
|
NCBI chr20:6,620,529...6,622,709
Ensembl chr20:6,620,529...6,622,689
|
|
G |
Cpb2 |
carboxypeptidase B2 |
decreases expression |
ISO |
orlistat results in decreased expression of CPB2 protein |
CTD |
PMID:16959692 |
|
NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
ISO |
Orlistat results in decreased expression of CPT1A protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CPT2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
Orlistat results in increased expression of CYP3A4 mRNA; Orlistat results in increased expression of CYP3A4 protein |
CTD |
PMID:20599501 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
decreases activity |
ISO |
orlistat results in decreased activity of DAGLA protein |
CTD |
PMID:16466961 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
orlistat results in increased expression of DDIT3 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
orlistat results in increased expression of DDIT4 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases phosphorylation multiple interactions |
ISO |
orlistat results in increased phosphorylation of EIF2A protein orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:17283163 PMID:20577697 |
|
NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases response to substance multiple interactions |
ISO |
EIF2AK3 gene mutant form results in increased susceptibility to orlistat orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:17283163 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
increases phosphorylation |
ISO |
orlistat results in increased phosphorylation of EIF4E protein |
CTD |
PMID:18796435 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
affects response to substance decreases expression affects localization |
ISO |
ERBB2 protein affects the susceptibility to orlistat orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein orlistat affects the localization of ERBB2 protein |
CTD |
PMID:15870086 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA] |
CTD |
PMID:17283163 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
increases expression |
ISO |
orlistat results in increased expression of ETV4 protein |
CTD |
PMID:15870086 |
|
NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Orlistat results in decreased expression of FABP1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
Orlistat results in decreased expression of FAS mRNA |
CTD |
PMID:32347045 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
affects binding affects response to substance multiple interactions decreases activity decreases expression |
ISO |
orlistat analog binds to FASN protein FASN protein affects the susceptibility to orlistat [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [Orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; Orlistat binds to and results in decreased activity of FASN protein; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone] orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein [orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid] Orlistat results in decreased expression of FASN protein |
CTD |
PMID:15026345 PMID:15138278 PMID:15870086 PMID:17012255 PMID:17618296 PMID:17847090 PMID:18281512 PMID:18710210 PMID:18723500 PMID:20148945 PMID:20577697 PMID:21213365 PMID:30667213 PMID:32045588 PMID:33476690 More...
|
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gcg |
glucagon |
multiple interactions decreases expression decreases secretion |
ISO |
orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein] orlistat results in decreased expression of GCG protein orlistat results in decreased secretion of GCG protein |
CTD |
PMID:12915676 PMID:18647814 PMID:19837920 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
ISO |
orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein] |
CTD |
PMID:15998659 PMID:17138722 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Gip |
gastric inhibitory polypeptide |
decreases expression |
ISO |
orlistat results in decreased expression of GIP protein |
CTD |
PMID:12915676 |
|
NCBI chr10:80,968,360...80,976,506
Ensembl chr10:80,968,352...80,976,503
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein] |
CTD |
PMID:29479035 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GPX1 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx8 |
glutathione peroxidase 8 |
increases expression |
ISO |
orlistat results in increased expression of GPX8 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 2:44,676,448...44,680,042
Ensembl chr 2:44,676,454...44,680,195
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GSR protein] |
CTD |
PMID:32450208 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
decreases expression |
ISO |
orlistat results in decreased expression of HBA1 protein modified form |
CTD |
PMID:19207292 PMID:19461584 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
orlistat inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein] |
CTD |
PMID:25087745 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
orlistat results in increased expression of HSPA5 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
Orlistat results in increased expression of IL10 mRNA |
CTD |
PMID:32450208 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:21088047 PMID:32045588 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of INS1 protein] |
CTD |
PMID:25087745 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
decreases expression increases expression affects expression multiple interactions |
ISO |
orlistat results in decreased expression of INS protein orlistat results in increased expression of INS protein orlistat affects the expression of INS protein [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:10095983 PMID:11274935 PMID:12915676 PMID:33476690 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kdelr3 |
KDEL endoplasmic reticulum protein retention receptor 3 |
increases expression |
ISO |
orlistat results in increased expression of KDELR3 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression |
ISO |
orlistat results in decreased expression of KDR protein |
CTD |
PMID:17012255 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Krt81 |
keratin 81 |
increases expression |
ISO |
orlistat results in increased expression of KRT81 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 7:132,577,112...132,582,238
Ensembl chr 7:132,576,492...132,582,170
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
orlistat inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein] |
CTD |
PMID:25087745 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lep |
leptin |
multiple interactions |
ISO EXP |
orlistat inhibits the reaction [Dietary Fats results in increased expression of LEP protein] |
CTD |
PMID:21332399 PMID:25087745 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipf |
lipase F, gastric type |
decreases activity |
ISO |
orlistat results in decreased activity of LIPF protein |
CTD |
PMID:11408251 PMID:12381337 |
|
NCBI chr 1:231,493,498...231,511,845
Ensembl chr 1:231,493,498...231,511,845
|
|
G |
Lpl |
lipoprotein lipase |
decreases activity multiple interactions |
ISO EXP |
orlistat results in decreased activity of LPL protein orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein] [orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides |
CTD |
PMID:12388125 PMID:12573449 PMID:15910848 PMID:15994321 PMID:18698144 PMID:25087745 More...
|
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32045588 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Napepld |
N-acyl phosphatidylethanolamine phospholipase D |
decreases activity |
EXP |
orlistat results in decreased activity of NAPEPLD protein |
CTD |
PMID:16466961 |
|
NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP ISO |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 mRNA] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:32450208 PMID:33476690 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein] |
CTD |
PMID:32450208 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npy |
neuropeptide Y |
increases expression |
ISO |
orlistat results in increased expression of NPY protein |
CTD |
PMID:15962606 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
orlistat results in increased activity of NR1I2 protein |
CTD |
PMID:20599501 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Orlistat binds to and results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:31312845 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nts |
neurotensin |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; Orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein] |
CTD |
PMID:18303078 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[orlistat co-treated with Thapsigargin] results in increased cleavage of PARP1 protein orlistat results in increased cleavage of PARP1 protein |
CTD |
PMID:15870086 PMID:17283163 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein] |
CTD |
PMID:32045588 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
decreases activity multiple interactions |
ISO |
orlistat results in decreased activity of PLA2G7 protein [orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein |
CTD |
PMID:16911813 PMID:18513463 PMID:18657971 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Pnlip |
pancreatic lipase |
decreases secretion decreases activity multiple interactions affects folding |
ISO EXP |
orlistat results in decreased secretion of PNLIP protein orlistat results in decreased activity of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein] orlistat affects the folding of PNLIP protein [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] |
CTD |
PMID:11408251 PMID:11668201 PMID:12381337 PMID:15158758 PMID:19346257 |
|
NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654
|
|
G |
Pnliprp2 |
pancreatic lipase related protein 2 |
decreases activity |
ISO EXP |
orlistat results in decreased activity of PNLIPRP2 protein Orlistat results in decreased activity of PNLIPRP2 protein |
CTD |
PMID:9822688 PMID:17401110 |
|
NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity |
ISO |
orlistat results in increased activity of PON1 protein |
CTD |
PMID:11820148 PMID:17134960 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Orlistat results in increased expression of PPARG mRNA |
CTD |
PMID:32347045 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
decreases expression |
ISO |
Orlistat results in decreased expression of PPT1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048
|
|
G |
Ppy |
pancreatic polypeptide |
multiple interactions |
ISO |
orlistat inhibits the reaction [Triglycerides results in increased secretion of PPY protein] |
CTD |
PMID:15998659 |
|
NCBI chr10:87,054,747...87,056,044
Ensembl chr10:87,054,756...87,055,455
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP ISO |
orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein] orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein] |
CTD |
PMID:18390901 PMID:19167487 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression multiple interactions |
ISO |
Orlistat results in increased expression of PTEN protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein] |
CTD |
PMID:32045588 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein] |
CTD |
PMID:32045588 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pyy |
peptide YY |
decreases secretion multiple interactions |
ISO |
orlistat results in decreased secretion of PYY protein orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein] |
CTD |
PMID:15998659 PMID:17138722 PMID:18647814 |
|
NCBI chr10:87,061,155...87,062,278
Ensembl chr10:87,061,161...87,061,815
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
orlistat results in decreased phosphorylation of RB1 protein |
CTD |
PMID:15138278 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of RELA mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Sec24d |
SEC24 homolog D, COPII coat complex component |
increases expression |
ISO |
orlistat results in increased expression of SEC24D mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 2:211,418,557...211,526,588
Ensembl chr 2:211,418,623...211,526,587
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
multiple interactions decreases expression |
ISO |
[orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein orlistat results in decreased expression of SKP2 protein |
CTD |
PMID:15138278 |
|
NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
orlistat inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein] Orlistat results in decreased expression of SREBF1 protein |
CTD |
PMID:32045588 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:33476690 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA] |
CTD |
PMID:15994321 PMID:32045588 PMID:32450208 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
orlistat results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:18796435 PMID:21406729 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of TP53 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA] |
CTD |
PMID:17283163 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|